Founded with love, rooted in nature.

What Is 13-OH Corydalis? The New Botanical Marketed as a 7-OH Alternative

13-OH Corydalis effects and risks graphic with purple flowers and dried rhizomes

Table of Contents

Key Points

  • 13-OH Corydalis is an emerging botanical-market ingredient. Manufacturers describe it as a hydroxylated Corydalis-derived alkaloid and are incorporating it into products promoted as alternatives to concentrated 7-hydroxymitragynine (7-OH).
  • 13-OH is marketed as distinct from 7-OH. Although their names are similar, 7-OH is associated with kratom, while products labeled 13-OH claim to use chemistry derived from Corydalis yanhusuo.
  • The underlying plant has a history of traditional medicinal use. Corydalis contains alkaloids such as tetrahydropalmatine (THP), which researchers have investigated for their effects on pain and the central nervous system.
  • Independent research on marketed 13-OH formulations is extremely limited. Research on ordinary Corydalis extracts or purified THP cannot establish the effects, safety, or potency of a product sold as 13-OH.
  • Corydalis supplements have documented quality and safety concerns. Research has identified substantial differences in alkaloid concentrations between products, while published case reports have associated Corydalis-containing preparations with liver injury.
  • 13-OH is not an established treatment for opioid withdrawal. There is no reliable clinical evidence that commercially marketed 13-OH products can safely replace 7-OH, prevent withdrawal, or treat opioid use disorder.
  • How Brooks Helps: Brooks Healing Center provides medical detox, residential addiction treatment, medication-assisted treatment (MAT), and continued recovery support for people struggling with kratom, 7-OH, opioids, and other substances.

The market for kratom and 7-hydroxymitragynine alternatives has changed considerably throughout 2026. As states restrict kratom products and federal regulators address concentrated and chemically modified alkaloids, manufacturers are introducing new ingredients that promise experiences similar to products consumers can no longer readily purchase.

One of the newer names appearing in this market is 13-OH Corydalis.

At first glance, the name sounds like another version of 7-OH. Both abbreviations contain a number followed by OH, and some retailers describe 13-OH-containing formulations as alternatives for people who previously used concentrated kratom alkaloids.

The chemistry behind those claims is more complicated, however. Corydalis is a different plant from kratom, and research on its established alkaloids does not automatically explain how a newly marketed 13-OH ingredient behaves in the human body.

That distinction matters, particularly for people who are physically dependent on 7-OH and considering another supplement to manage withdrawal.

What Is Corydalis Yanhusuo?

Corydalis yanhusuo is a flowering plant native to parts of East Asia. It belongs to the Papaveraceae family, which also includes the opium poppy, although belonging to the same botanical family does not mean that Corydalis contains morphine or produces the same effects.

The plant’s underground stem, or rhizome, has been used in traditional Chinese medicine, particularly in preparations intended to address discomfort and pain.

Researchers have identified numerous naturally occurring alkaloids in Corydalis, including:

  • Tetrahydropalmatine (THP)
  • Dehydrocorydaline
  • Corydaline
  • Protopine
  • Dehydrocorybulbine

These compounds have attracted scientific interest because of their activity in the nervous system and other biological pathways.

Tetrahydropalmatine is among the most extensively investigated. Research has examined its interactions with dopamine receptors and its potential effects on pain perception, sedation, and reward-related behavior.

However, much of this research involves isolated compounds, animal models, or laboratory experiments. Those findings cannot necessarily predict what happens when someone takes a commercially manufactured Corydalis supplement.

The same limitation applies to any newly developed derivative of the plant’s alkaloids.

What Exactly Is 13-OH Corydalis?

The term 13-OH Corydalis has appeared in 2026 marketing for botanical ingredients and combination tablets.

Commercial suppliers describe the ingredient as a hydroxylated alkaloid associated with Corydalis yanhusuo.

In chemical terminology, OH refers to a hydroxyl group. The number ordinarily identifies a position within a particular molecular structure.

That naming convention is not unusual. What remains uncertain is whether products using the term 13-OH consistently contain the same independently characterized chemical substance.

A supplier’s description of an ingredient is not equivalent to published structural identification, independent laboratory confirmation, or human clinical research.

As of November 2026, the publicly available research reviewed for this article does not establish a well-characterized clinical safety profile for commercially marketed 13-OH Corydalis.

Is 13-OH Naturally Occurring or Manufactured?

Manufacturers describe 13-OH as plant-derived, but this wording leaves an important question unanswered.

An ingredient extracted directly from a plant is not necessarily the same as one produced through chemical modification of a naturally occurring plant compound.

Both may be marketed as botanical-derived, even though their manufacturing processes and final chemical compositions differ.

Without independently verified chemical identification and manufacturing information, consumers cannot reliably determine whether a specific 13-OH product contains a naturally occurring constituent, a modified alkaloid, or a proprietary mixture.

This also means that the safety of traditional Corydalis preparations cannot automatically be applied to concentrated 13-OH ingredients.

13-OH vs. 7-OH vs. Tetrahydropalmatine

The similar names can make these substances appear more closely related than the available evidence supports.

Characteristic 13-OH Corydalis 7-Hydroxymitragynine (7-OH) Tetrahydropalmatine (THP)
Associated plant Corydalis yanhusuo, according to manufacturers Kratom (Mitragyna speciosa) Corydalis yanhusuo
Chemical classification Marketed as a modified Corydalis alkaloid; identity requires verification Kratom-associated indole alkaloid Tetrahydroprotoberberine alkaloid
Opioid receptor activity Not adequately established for commercial formulations Documented opioid receptor activity Different and more complex pharmacology; not established as equivalent to 7-OH
Human research No adequate independent clinical evidence identified for marketed 13-OH Human exposure and safety concerns documented Limited human research; more substantial preclinical literature
Dependence potential Unknown Dependence and withdrawal documented Insufficient evidence to define dependence risk across products
FDA-approved addiction treatment No No No
Major concern Unverified effects, composition, and safety Opioid toxicity, dependence, and overdose Sedation, potential toxicity, and liver injury concerns

The biggest difference is the amount and quality of evidence available.

Researchers have studied 7-OH as an opioid-active compound, and the FDA has warned about the risks associated with concentrated 7-OH products. THP has also been examined in scientific research, although its clinical applications remain limited.

By comparison, commercial 13-OH formulations lack the independent evidence necessary to establish comparable effects or safety.

An ingredient containing OH in its name should not be assumed to behave like 7-OH.

For more information about concentrated kratom alkaloids and newer replacement products, read our investigation into botanical blends marketed as 7-OH alternatives.

What Are the Effects of 13-OH Corydalis?

Manufacturers position some 13-OH-containing products around mood, energy, relaxation, discomfort, or experiences resembling those associated with kratom extracts.

Those descriptions are marketing claims, not established clinical findings.

The scientific literature provides considerably more information about ordinary Corydalis alkaloids than about products specifically labeled 13-OH.

Pain and Discomfort

Corydalis has a long history of traditional use for pain-related complaints.

Researchers have investigated several of its constituents in experimental pain models. Some studies have reported pain-modulating effects involving dopamine signaling, sodium channels, and other pathways.

However, evidence from laboratory and animal experiments does not demonstrate that a commercially available 13-OH extract reliably relieves pain in people.

It also does not establish that Corydalis is a suitable replacement for prescription pain medication.

Relaxation and Sedation

Sedating effects have been described with certain Corydalis preparations and tetrahydropalmatine-containing products.

These effects are relevant because some people may assume a calming botanical is inherently safer than an opioid or prescription sedative.

Sedation can still create safety problems, particularly when products are combined with alcohol, benzodiazepines, opioids, sleep medications, or other substances that impair alertness.

The specific sedating effects and interaction risks of marketed 13-OH formulations have not been adequately characterized.

Mood and Reward Pathways

Some Corydalis alkaloids interact with dopamine-related pathways involved in motivation, reward, and movement.

That has led researchers to explore whether compounds such as THP might eventually have applications in substance-use treatment.

This research is preliminary and should not be mistaken for proof that Corydalis or 13-OH treats addiction.

A substance being investigated for effects on reward pathways is not automatically safe for someone with a history of opioid dependence.

Are 13-OH Corydalis Products Safe?

There is not enough independent human research to establish that 13-OH Corydalis products are safe.

More importantly, safety cannot be determined by looking at the plant name alone.

Corydalis-containing supplements have already raised questions about inconsistent alkaloid concentrations, adverse reactions, and liver toxicity. These findings concern Corydalis preparations generally, not necessarily the specific chemical sold as 13-OH.

Research Found Significant Differences Between Corydalis Supplements

A study published in Frontiers in Pharmacology in January 2025 examined 14 commercially available Corydalis yanhusuo dietary supplements.

Researchers measured 19 alkaloids and found substantial variation between products.

Some preparations contained alkaloid concentrations comparable to natural Corydalis extracts. Others contained much smaller amounts or concentrations below the researchers’ quantification limits.

One product contained an unusually high proportion of tetrahydropalmatine relative to its overall alkaloid profile, raising questions about possible enrichment or adulteration.

The findings demonstrate why two supplements bearing the same botanical name may not contain comparable amounts of their active chemicals.

For newer products marketed as 13-OH, reliable chemical identification and independent testing are particularly important.

Corydalis Has Been Associated With Liver Injury

A 2023 report in ACG Case Reports Journal described two patients who experienced liver injury associated with a sleep supplement containing Corydalis.

In one case, liver enzyme changes corresponded with stopping and restarting the product. In the second, liver function improved after the supplement was discontinued.

The supplement also contained other ingredients, so these cases cannot establish that every Corydalis product—or 13-OH specifically—causes liver damage.

They do, however, demonstrate that botanical preparations can have clinically significant adverse effects.

Someone with existing liver disease or unexplained symptoms such as jaundice, dark urine, persistent nausea, or abdominal pain should seek medical evaluation rather than continuing an unfamiliar supplement.

Combining Multiple Active Ingredients Creates Additional Uncertainty

Some 13-OH products are not sold as standalone Corydalis extracts.

For example, manufacturers have marketed combination tablets containing 13-OH-labeled Corydalis material alongside mitragynine and paraxanthine.

These ingredients come from different pharmacological categories. Mitragynine is a kratom alkaloid with opioid-related activity, while paraxanthine is a caffeine-related stimulant compound.

Research on individual ingredients cannot establish the safety of the finished combination.

A tablet containing multiple active substances may produce effects that are difficult to predict, particularly when someone is also taking prescription medication or other psychoactive products.

Why Ingredient Testing Matters

Consumers often encounter certificates of analysis, commonly called COAs, when researching newer supplements.

A legitimate laboratory report can provide useful information about a specific product sample, but the details matter.

Important questions include:

  • Does the report identify the actual chemical being measured, rather than relying only on a commercial abbreviation?
  • Was the analysis conducted by an independent laboratory using a suitable validated method?
  • Does the tested batch match the product being sold?
  • Were relevant contaminants and undeclared psychoactive substances included in the testing?
  • Does the report establish ingredient identity and concentration, rather than making unsupported safety claims?

A certificate showing that a product contains no detectable 7-OH does not automatically establish that the product is free of other opioid-active chemicals.

Likewise, an ingredient testing report cannot demonstrate that a newly marketed compound is safe for daily use, lacks dependence potential, or is effective for opioid withdrawal.

These distinctions have become increasingly important as unfamiliar products enter the kratom-alternative market.

Can 13-OH Corydalis Cause Addiction or Withdrawal?

At present, there is insufficient human evidence to determine whether independently verified 13-OH Corydalis produces physical dependence, withdrawal, or compulsive-use patterns.

That does not mean the risks are absent. It means the necessary research has not been completed.

There is also a significant difference between a product containing only a Corydalis-derived ingredient and one containing kratom alkaloids or other psychoactive compounds.

If a product contains mitragynine, for example, its dependence potential cannot be assessed solely by examining the Corydalis component.

People using multiple extracts may also have difficulty identifying which substance is responsible for a particular effect.

If someone experiences increasing tolerance, feels unable to stop using a product, or develops symptoms when doses are missed, those concerns warrant professional evaluation.

The priority should be understanding what the person is actually taking, rather than assuming that every product advertised as botanical has a predictable safety profile.

Can 13-OH Replace 7-OH or Help With Kratom Withdrawal?

There is no reliable clinical evidence showing that 13-OH Corydalis safely treats withdrawal from 7-hydroxymitragynine.

This is particularly important because concentrated 7-OH products have opioid activity and can cause physical dependence.

The FDA has documented withdrawal symptoms associated with 7-OH exposure, including restlessness, body aches, insomnia, fatigue, gastrointestinal distress, irritability, and cold sweats.

Someone who has developed dependence on an opioid-active product may experience withdrawal when that exposure is reduced or stopped.

Switching to a different botanical does not necessarily prevent those symptoms, especially if the replacement has no established ability to address opioid withdrawal.

It may also introduce new risks if the substitute contains additional psychoactive ingredients.

At Brooks Healing Center, we encourage people experiencing withdrawal from kratom or concentrated 7-OH to seek medical guidance instead of attempting to manage dependence through unverified supplements.

Our kratom and 7-OH addiction treatment program addresses both the physical effects of substance use and the behavioral patterns that can make stopping difficult.

For some individuals, treatment may involve medical detox followed by residential care and continued recovery support.

Is 13-OH Corydalis Legal in Tennessee?

The legal situation is different from the scientific question of whether 13-OH is safe.

Tennessee’s 2026 kratom prohibition targets kratom and substances covered by the law’s definitions. Corydalis is a botanically distinct plant, and a product containing Corydalis alone should not automatically be assumed to have the same legal classification as a kratom product.

However, the precise composition of a product matters.

A tablet marketed as containing 13-OH may also include mitragynine, concentrated kratom alkaloids, or other regulated ingredients.

Federal controlled-substance scheduling, state laws, and FDA rules governing supplements and drug claims are also separate regulatory systems.

The absence of a compound from a controlled-substance schedule does not establish that it can legally be sold as a dietary supplement or marketed to treat withdrawal.

Consumers should not rely on phrases such as “legal 7-OH alternative” or “compliant botanical” without verifying the actual ingredients and applicable law.

For current information about restrictions, see our 2026 kratom and 7-OH ban by state guide.

What Should Someone Do After a Bad Reaction to a Corydalis Product?

A new supplement should not be dismissed as harmless simply because it came from a smoke shop, wellness retailer, or botanical manufacturer.

Symptoms that deserve prompt medical attention include severe dizziness, confusion, persistent vomiting, unusual drowsiness, or signs of liver problems.

If someone is unconscious, has slowed or abnormal breathing, or cannot be awakened, call 911 immediately. If opioid exposure is possible, administer naloxone when available while emergency services are responding.

For a suspected poisoning without immediately life-threatening symptoms, Poison Control can be reached at 1-800-222-1222.

Preserving the product packaging and ingredient information may also help medical professionals identify possible exposures.

Frequently Asked Questions About 13-OH Corydalis

Is 13-OH the same as 7-OH?

No. The two names refer to different claimed chemical identities. 7-OH is a kratom-associated alkaloid with documented opioid receptor activity, whereas 13-OH Corydalis is marketed as a Corydalis-derived ingredient whose commercial formulations lack adequate independent clinical characterization.

Does 13-OH Corydalis contain opioids?

Corydalis is not the same plant as kratom, and the opioid-like activity established for 7-OH cannot automatically be assigned to Corydalis alkaloids. However, some 13-OH-labeled combination products also contain kratom-derived ingredients, so the complete product composition must be considered.

Does 13-OH get you high?

Commercial descriptions suggest that some products are intended to produce noticeable mood-related or psychoactive effects. Independent human studies have not established the specific intoxicating effects, potency, or safety profile of 13-OH Corydalis itself.

Is 13-OH stronger than tetrahydropalmatine?

There is insufficient independent evidence to make a reliable potency comparison. Manufacturers may distinguish 13-OH from THP, but that does not establish how the substances compare in humans or whether the advertised material has been independently identified.

Can Corydalis help with pain?

Certain Corydalis alkaloids have demonstrated pain-modulating activity in experimental research, and the plant has a history of traditional use for discomfort. This does not establish that commercially marketed 13-OH is an effective or safe pain treatment.

Can 13-OH prevent kratom or 7-OH withdrawal?

No clinical evidence establishes 13-OH as an effective treatment for kratom or 7-OH withdrawal. People who have developed dependence on concentrated kratom alkaloids should consult a medical professional about appropriate withdrawal management.

Is 13-OH FDA-approved?

No FDA-approved medication containing 13-OH Corydalis has been identified. Its marketing as a botanical ingredient does not establish approval, safety, or effectiveness for treating any medical condition.

Is 13-OH safe to combine with alcohol or other medications?

Its interaction profile has not been adequately studied. Because certain Corydalis alkaloids have central nervous system effects and some commercial formulations contain additional psychoactive substances, combining these products with alcohol, opioids, benzodiazepines, or other medications may create unpredictable risks.

Get Help for Kratom, 7-OH, and Botanical Product Dependence at Brooks Healing Center

Corydalis is not a newly discovered plant, but products marketed as 13-OH represent a newer development in the rapidly changing market for kratom and 7-OH alternatives.

The available evidence does not establish that these products reproduce the effects of 7-OH, safely manage withdrawal, or provide an appropriate substitute for medical treatment.

For someone already struggling with dependence, moving from one unfamiliar product to another can make an already complicated situation harder to manage.

Brooks Healing Center provides addiction treatment between Nashville and Chattanooga in Normandy, Tennessee. Our programs include medically supervised detox, residential treatment, medication-assisted treatment, partial hospitalization, sober living, and ongoing recovery support.

When clinically appropriate, our medication-assisted treatment program incorporates FDA-approved medications for opioid use disorder, including buprenorphine-based treatment and extended-release injectable options such as Sublocade and Brixadi.

Our team evaluates each person’s substance use history, withdrawal symptoms, medical concerns, and individual treatment needs before recommending care.

If you or someone you love is struggling with 7-OH, kratom products, or other substances, call CALL NOW: 931-486-8824 to speak confidentially with our admissions team. We can discuss treatment options, verify insurance benefits, and help you determine an appropriate next step.


Sources

Dialed Editorial. (2026, August 12). What is 13-OH? Corydalis extract explained. Dialed. https://feeldialed.com/blog/what-is-13-oh-corydalis

Commercial source included only to document how 13-OH is marketed and described by a manufacturer; it is not independent clinical evidence.

Engman, S., Puello, F., Khoury, K., Miller, D. M., Isidan, K., & Shah, D. (2023). Corydalis and drug-induced liver injury: A series of 2 cases. ACG Case Reports Journal, 10(12), e01230. https://doi.org/10.14309/crj.0000000000001230

Luis, P. B., & Schneider, C. (2025). Large variability in the alkaloid content of Corydalis yanhusuo dietary supplements. Frontiers in Pharmacology, 15, Article 1518750. https://doi.org/10.3389/fphar.2024.1518750

Substance Abuse and Mental Health Services Administration. (n.d.). Treatment options for substance use disorder. https://www.samhsa.gov/substance-use/treatment/options

Tian, B., Tian, M., & Huang, S. M. (2020). Advances in phytochemical and modern pharmacological research of Rhizoma Corydalis. Pharmaceutical Biology, 58(1), 265–275. https://doi.org/10.1080/13880209.2020.1741651

U.S. Food and Drug Administration. (n.d.). Products containing 7-OH can cause serious harm. https://www.fda.gov/consumers/consumer-updates/products-containing-7-oh-can-cause-serious-harm